UK quoted biotech performance and investor base in 2021

This report is an exclusive analysis of the performance of the UK-quoted biotech sector and the breadth of its investor base by Radnor Capital Partners on behalf of the BIA.

Over the course of 2021, the broad biotech index returned +16% vs +14% for the FTSE All Share. Cell & Gene Therapy, Research Tools, Medical Devices and Small Molecule all returned over 20%. 2021 has also seen a further increase in the number of new investors active in the sector, although not at the pace seen in 2020.